Investor relations

Denny’s Corporation to Participate at the Stephens Annual Investment Conference on November 17, 2022

Retrieved on: 
Thursday, November 10, 2022
Denny's, GLOBE, Keke, Restaurant, Webcast, Investor relations, Central Time, NASDAQ, Company, Corporation, Conference, Hotel

SPARTANBURG, S.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Dennys Corporation (the "Company") (NASDAQ: DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's"), today announced that the Company will participate in the Stephens Annual Investment Conference in Nashville, Tennessee.

Key Points: 
  • SPARTANBURG, S.C., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Dennys Corporation (the "Company") (NASDAQ: DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's"), today announced that the Company will participate in the Stephens Annual Investment Conference in Nashville, Tennessee.
  • On Thursday, November 17, 2022, the Company will conduct investor meetings with a presentation by Robert Verostek, Chief Financial Officer, at 1:00 p.m. Central Time.
  • Dennys Corporation is one of Americas largest full-service restaurant chains based on number of restaurants.
  • Denny's Corporation consists of the Dennys brand and the Kekes brand.

Duolingo Announces 51% DAU Growth and Record Bookings and Revenue in Third Quarter 2022; Raises Full Year Guidance

Retrieved on: 
Thursday, November 10, 2022
Review, Private Securities Litigation Reform Act, Health, Risk, Investment, Calendar, Learning, Form 10-Q, Google Play, Education, Shithead (card game), Technology, Active users, Investor relations, Maus, Securities Act of 1933, Mission statement, SEC, App Store (iOS/iPadOS), Securities Exchange Act of 1934, Time, Adjustment, GAAP, Social media, Growth, Industry, Bank, Mobile phone

Duolingo will host a video webcast to discuss its quarterly results today, November10, 2022 at 5:30 p.m.

Key Points: 
  • Duolingo will host a video webcast to discuss its quarterly results today, November10, 2022 at 5:30 p.m.
  • This live webcast and related materials will be publicly available and can be accessed at investors.duolingo.com.
  • Subscription bookings represent the amounts we receive from a purchase of a subscription to Super Duolingo (formerly called Duolingo Plus).
  • MAUs are defined as unique Duolingo users who engage with our mobile language learning application or the language learning section of our website each month.

Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, November 10, 2022
Osteomalacia, Investment, Risk, IVBM, U.S. Securities and Exchange Commission, Research and development, Annual general meeting, Nasdaq, Private Securities Litigation Reform Act, Blood, Investor relations, Hearing loss, ATP, Disease, Consultant, Mortality, CD73, R, Annual report, Compte rendu, Pseudoxanthoma elasticum, Myocardial infarction, Skeleton, Calcification, Infant, Company, Generalized arterial calcification of infancy, Rickets, Research, ABCC6, Pyrophosphate, Skin, Therapy, Administration, Security (finance), PXE, FDA, Stroke, Medical imaging, Pharmaceutical industry

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today reported financial results for the third quarter ended September 30, 2022 and provided recent business highlights.

Key Points: 
  • Preclinical data supporting INZ-701's potential to treat intimal proliferation was featured at the International Vascular Biology Meeting (IVBM) 2022 Annual Meeting in October.
  • Cash Position and Financial Guidance Cash, cash equivalents, and investments were $141.5 million as of September 30, 2022.
  • Research and Development (R&D) Expenses R&D expenses were$12.2 millionfor the quarter ended September 30, 2022, compared to$9.3 millionfor the prior-year period.
  • General and Administrative (G&A) Expenses G&A expenses were$4.7 millionfor the quarter ended September 30, 2022, compared to$4.9 millionfor the prior-year period.

Titan Medical Reports Financial Results for the Third Quarter 2022, and Announces Special Shareholder Meeting

Retrieved on: 
Thursday, November 10, 2022
Vance, GLOBE, Forward-looking statement, Marketing, TMD, Food, Research and development agreement, Webcast, RAS, Intention, Development, Classification, IDE, Investor relations, Regulation of tobacco by the U.S. Food and Drug Administration, R, Enos, News, Compliance, Time, Software, Company, Conference, Engineering, De novo, Medtronic, Surgeon, TSX, Growth, CEO, Motion, FDA, Trial of the century, Medical device, Risk management, Nasdaq, Titan, G&A

Titan is completing the final steps prior to the anticipated delivery of the first Enos system to its Chapel Hill facility before year-end 2022.

Key Points: 
  • Titan is completing the final steps prior to the anticipated delivery of the first Enos system to its Chapel Hill facility before year-end 2022.
  • Following submission, we expect to finalize our clinical trial design and continue to plan our commercialization strategy for the U.S. market.
  • Vance added, After careful consideration, the company has also decided to propose a consolidation of common shares to its shareholders.
  • ET today (November 10, 2022) to discuss the companys financial results for the three months ended September 30, 2022, and recent business highlights.

Vericel to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Financial Services Forum, Knee, Debridement, Sports medicine, Investor relations, CG, Webcast, NASDAQ, Digital health, CFO, Company, Conference, Chondrocyte, Patient, CEO, Thermal burn, Pharmaceutical industry, Diagnosis

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Company leadership will present at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Service Forum and the Stephens Annual Investment Conference.
  • Nick Colangelo, President and CEO will present at the CG MedTech, Diagnostics, and Digital Health & Service Forum at 10:00 a.m.
  • ET at the Stephens Annual Investment Conference.
  • Webcasts of both presentations will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com .

Milestone Scientific Schedules Third Quarter 2022 Financial Results and Business Update Conference Call

Retrieved on: 
Thursday, November 10, 2022
GLOBE, MLSS, Telephone, Safety, Injection, NYSE, Technology, Investor relations, Pharmaceutical industry

The conference call will be available via telephone by dialing toll free 877-545-0523 for U.S. callers or +1 973-528-0016 for international callers and by entering the access code: 570917.

Key Points: 
  • The conference call will be available via telephone by dialing toll free 877-545-0523 for U.S. callers or +1 973-528-0016 for international callers and by entering the access code: 570917.
  • A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2306/47097 or on the Investor Relations section of the Companys website at https://www.milestonescientific.com/investors .
  • Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications.
  • Milestone Scientifics computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety.

Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences

Retrieved on: 
Thursday, November 10, 2022
GLOBE, Evercore, Nasdaq, Investor relations, Psychiatry, Company, Cell, Conference, Therapy, Central nervous system, CNS, Pharmaceutical industry

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming investor conferences:

Key Points: 
  • NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming investor conferences:
    Tuesday, November 29, 2022 at 12:35 pm ET.
  • Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
  • Intra-Cellular Therapiesis a biopharmaceutical company founded onNobelprize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body.
  • The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

Wabash to Participate in Stephens Annual Investment Conference

Retrieved on: 
Thursday, November 10, 2022
Transport, EPS, GLOBE, Conference, WNC, Solution, NYSE, EBITDA, Investor relations, Renewable energy, Rail freight transport

To access the live or archived webcast, visit the Investor Relations section of Wabashs website at ir.onewabash.com .

Key Points: 
  • To access the live or archived webcast, visit the Investor Relations section of Wabashs website at ir.onewabash.com .
  • As the innovation leader of connected solutions for the transportation, logistics and distribution industries, Wabash (NYSE: WNC) is Changing How the World Reaches You.
  • Headquartered in Lafayette, Indiana, the companys mission is to enable customers to succeed with breakthrough ideas and solutions that help them move everything from first to final mile.
  • Wabash designs and manufactures a diverse range of products, including: dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food grade processing equipment.Learn more at www.onewabash.com .

Natural Gas Services Group Reschedules Third Quarter 2022 Earnings Release Date and Conference Call

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Webcast, Central Standard Time, NYSE, NGS, New, Investor relations, Company, Petroleum

Midland, Texas, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (NYSE:NGS), today announced that the Company is rescheduling its third quarter 2022 earnings release and conference call date to allow the Company adequate time to finalize its financial report.

Key Points: 
  • Midland, Texas, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Natural Gas Services Group, Inc. (NYSE:NGS), today announced that the Company is rescheduling its third quarter 2022 earnings release and conference call date to allow the Company adequate time to finalize its financial report.
  • The earnings release is now scheduled to be issued after the close of trading on the New York Stock Exchange on Monday, November 14, 2022.
  • About Natural Gas Services Group, Inc.
    NGS is a leading provider of gas compression technology and services to the energy industry.
  • The Company manufactures, fabricates, rents, sells and maintains natural gas compression technology for oil and natural gas upstream providers and midstream facilities.

Advantage Solutions Reports Third Quarter 2022 Financial Results and Provides Updated Guidance

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Forward-looking statement, Marketing, Investment, XIII, Nature, U.S. Securities and Exchange Commission, XV, Disclosure, Advantage, Environment, Xi, Depreciation, Classification, Investor relations, ADV, CPG, SEC, Annual report, Digital, NASDAQ, Exercise, Solution, Compte rendu, ID, Pressure, EBITDA, Company, 100,000, Griffin, Terminology, GAAP, Growth, Security (finance), Industry, Acquisition, COVID-19, Income, Renewable energy, Bank, Ridesharing company, Bookkeeping, Risk management, Adjustment

IRVINE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (Advantage, Advantage Solutions, the Company, we or our), a leading provider of outsourced sales and marketing services to consumer goods manufacturers and retailers, today reported financial results for its third quarter ended September 30, 2022.

Key Points: 
  • IRVINE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (Advantage, Advantage Solutions, the Company, we or our), a leading provider of outsourced sales and marketing services to consumer goods manufacturers and retailers, today reported financial results for its third quarter ended September 30, 2022.
  • Revenues were $1,051.1 million for the third quarter of 2022, representing an increase of $122.3 million, or 13.2%, from the third quarter 2021 revenues of $928.8 million.
  • ET on November 9, 2022 to discuss its third quarter 2022 financial performance and business outlook.
  • Advantage Solutions (NASDAQ: ADV) is a leading provider of outsourced sales and marketing solutions to consumer goods companies and retailers.